news
DNA epigenetic changes: a key cause of cancer
Analysis of cells shows many regions in DNA are differentially activated or inactivated in a cancer-specific manner.
List view / Grid view
Cancer
news
Understanding Z-RNA structure could provide new treatments
A $1.2 million grant has been given to observe how Z-RNA is formed and explore its benefits for various diseases.
article
Cancer drug discovery: protein-ligand interactions
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs…
news
New biomarker advances cancer treatments
Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.
news
Machine could make CAR T-cell therapy more accessible
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.
news
Key epitope can trigger tumour cell death
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
article
Novel method for early cancer diagnosis
A recent scientific collaboration, led by the Institute of Nuclear Physics of the Polish Academy of Sciences, has overcome measurement challenges, enabling reliable cancer diagnosis.
news
Human-derived proteins used in DREAM tool
CRISPR-DREAM tool used to activate insufficiently expressed genes and convert skin cells to induced pluripotent stem cells (iPSCs).
article
Insights into the critical initial phase of embryonic development
Researchers from the University of Helsinki and the National Institutes of Health (NIH) in the United States have made a new discovery: the ectoderm, one of the germ layers, does not lose its pluripotency during gastrulation, contrary to prior beliefs.
article
SRC-3: CoRegen’s revolutionary approach to cancer
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.
news
Childhood cancer survivors’ mortality risk
Researchers find genetic explanation for increased risk of developing second cancers.
news
Proteolysis: new method developed to target cancer cells
Researchers have found that targeting chimeras with click-release proteolysis activates specific molecules that target cancer cells without harming health cells.
news
Senescent immune cells promote lung tumour growth
A recent study sheds light on an unexpected discovery concerning macrophages, a vital type of white blood cell in the body's defence against infections and tumours.
news
Novel approach to overcome resistance to cancer drugs
Researchers at the University of Queensland have discovered a promising drug target capable of addressing drug resistance and preventing tumour regrowth in cancer patients.
news
Engineered immune cells for improved cancer defence
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
